Key Highlights

  • Eli Lilly rose 3.19% to $1,417.54 on October 30, 2026.
  • Third-quarter Revenue rose 39% to $24.4 billion, well ahead of forecasts.
  • Lilly raised its 2026 revenue guidance to $91 billion to $92 billion.
  • Mounjaro sales rose 65% to $10.7 billion in the quarter.

What made Eli Lilly (NYSE:LLY) stand out on Friday's list of most active stocks was its direction. While technology shares sank, the drugmaker climbed 3.19% to $1,417.54, building on a record close the day before, on Volume more than twice its normal level according to market data. The rally extended the market's reaction to a third-quarter report on Thursday in which Lilly beat revenue forecasts by a wide Margin and raised its full-year sales outlook by billions of dollars, driven by surging Demand for its diabetes and obesity drugs.

A second day of gains

Lilly reported results on Thursday, October 29, and the stock rose 6.6% that day to a record close of $1,373.70, according to market reports. Drug stocks rallied as a group that day even as the S&P 500 slipped 0.3%: Market Analysis said the Health Care Select Sector SPDR fund gained 2.4%, Merck (NYSE:MRK) rose 3.8% after its own Earnings beat and Johnson & Johnson (NYSE:JNJ) added 1.5%.

Friday's further gain came as investors shifted money away from technology. Market reports said healthcare stocks rose 0.7% to a record high on Friday and consumer staples gained 1.6%, even as Intel (NASDAQ:INTC)'s weak outlook and Amazon (NASDAQ:AMZN)'s spending plans drove a broad tech sell-off. The S&P 500 fell 1.82%, the Nasdaq Composite lost 2.86%, and the CBOE Volatility index jumped almost 13%, according to market data.

Analysts also moved to raise their targets. Scotiabank lifted its price target to $1,605 from $1,300 with an outperform rating, market reports said, and market data noted Argus raised its target to $1,550 from $1,300. Market reports said Jefferies (NYSE:JEF) raised its target to $1,610.

What Lilly does

Eli Lilly is an Indianapolis-based pharmaceutical company best known today for its incretin drugs, which mimic gut hormones to control blood sugar and appetite. Mounjaro treats type 2 diabetes, and Zepbound, which uses the same active ingredient, is approved for weight loss. The company also sells medicines in oncology, immunology and neuroscience and is developing next-generation obesity treatments, including the pill orforglipron, marketed as Foundayo, and the injectable retatrutide.

Results and guidance

Third-quarter revenue rose 39% to $24.4 billion, well ahead of the roughly $22.6 billion analysts expected, according to market reports. Mounjaro sales rose 65% to $10.7 billion and Zepbound brought in $5.35 billion. Adjusted earnings were $7.48 a share, beating the consensus estimate. Volume growth of 53% more than offset lower realized prices, market reports said. About $900 million of the quarter's revenue came from one-time items such as milestone payments and changes in rebate estimates. Even excluding those, revenue of about $23.5 billion topped forecasts, market analysis noted.

Lilly raised its 2026 revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion. It trimmed its adjusted earnings guidance to $35 to $36 a share from $35.50 to $36.50, reflecting $4.57 a share in acquired research charges taken in the quarter. Chief executive David Ricks said the company is in the middle of "the largest new category expansion in the history of the pharmaceutical industry." Addressing the large upward revision, he added: "we're beating on the up, that's better than missing on the down," according to market reports.

Ricks attributed much of the upside to two variables the company had not forecast: the ramp of Medicare's GLP-1 Bridge program, launched July 1, and cash-pay demand for weight-loss drugs among middle-income households outside the United States. More than 500,000 people have filled a prescription through the Bridge program, and Lilly's US president, Ilya Yuffa, said seven in ten new Bridge patients start on a Lilly drug, with about 80% of them new to incretin medicines.

Chief financial officer Lucas Montarce said Lilly reaches about one in ten US patients and two in a hundred elsewhere, which suggests a long runway if access keeps widening. The company also reported topline trial results on October 28 showing retatrutide lowered A1C, a measure of blood sugar, by 2.2%, versus 1.8% for Novo Nordisk (NYSE:NVO)'s Ozempic.

Valuation

At about 46.6 times trailing earnings, according to market data, Lilly is far more expensive than most large drugmakers. Market analysis put Lilly at about 31 times next-twelve-month earnings versus about 12 times for its main obesity rival, Novo Nordisk. The rally has also outrun some Wall Street targets: the consensus target of about $1,391 sits below Friday's close, even as several firms have lifted their numbers well above it. Market analysis noted the stock returned 68.6% over the past 12 months, versus 13.3% for the S&P 500, and that it was up 28.4% for the year through Thursday, compared with 19.9% for the healthcare sector fund.

The bull case

Bulls argue that Lilly is still early in a historic expansion of the obesity and diabetes market, and that its products are winning share. Volume growth is far outpacing price declines, government programs and international cash-pay channels are opening new markets, and the pipeline offers more shots on goal, including an oral option in Foundayo and a potentially more powerful injectable in retatrutide. Its defensive appeal also matters: the stock has a low Beta of 0.46, according to market data, and Friday showed it can rise when Growth Stocks are falling.

The bear case

Bears point to price erosion. US prices fell 10% in the third quarter excluding a favorable rebate adjustment, market reports said, and about $2 billion of 2026 revenue came from one-time items the company does not expect to repeat. Market data noted that about two-thirds of revenue is tied to GLP-1 drugs, that employers may resist covering weight-loss medicines, and that the valuation is elevated. TD Cowen's Steve Scala said investors need to know "when the surprise Factor runs its course."

Foundayo Decision and 2027 Guidance

A US regulatory decision on Foundayo for type 2 diabetes is expected in the fourth quarter. The stock goes ex-dividend on November 13, with a quarterly payout of $1.73 a share payable December 10, according to market data. Lilly will issue 2027 guidance with fourth-quarter results, expected in early 2027, where investors will compare its outlook with the roughly $103 billion Street revenue estimate cited in market reports.